CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More

Subodh Verma; Lawrence A Leiter; Deepak L Bhatt

doi:10.1016/j.cmet.2017.09.022

CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More

Cell Metab. 2017 Nov 7;26(5):703-705. doi: 10.1016/j.cmet.2017.09.022. Epub 2017 Oct 19.

Authors

Subodh Verma¹, Lawrence A Leiter², Deepak L Bhatt³

Affiliations

¹ Division of Cardiac Surgery, St Michael's Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada. Electronic address: vermasu@smh.ca.
² Division of Endocrinology and Metabolism, St Michael's Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada.
³ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 29056511
DOI: 10.1016/j.cmet.2017.09.022

Abstract

Despite overwhelming basic science linking inflammation to the pathobiology of atherothrombosis, the specific clinical evidence indicating cardiovascular benefits from anti-inflammatory pharmacotherapy has been lacking. The CANTOS trial (Ridker et al., 2017a) now provides the first largescale proof of concept that inflammasome targeting can reduce cardiovascular events-and, surprisingly, lung cancer.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Atherosclerosis*
Calculi*
Humans
Inflammasomes

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Inflammasomes
canakinumab